Vimarsana
Biggest News Aggregation in the World

Page 14 - Adaptive Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adaptive Research Today - Breaking & Trending Today

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma - Vimarsana News

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma

/PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced its lead candidate VT1021 will...

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial | Anticoagulation | JAMA - Vimarsana News

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial | Anticoagulation | JAMA

This randomized clinical trial evaluates the benefits and risks of the addition of a P2Y12 inhibitor to anticoagulant therapy compared with anticoagulant therap

Grant Funding Supports Research on Kintara's VAL-083 in GBM Models - Vimarsana News

Grant Funding Supports Research on Kintara's VAL-083 in GBM Models

The Luxembourg National Research Fund and Cancer Foundation Luxembourg will fund researchers using tumor models and transcriptomics to elucidate VAL-083's mechanism in GBM.

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma - Vimarsana News

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma - Vimarsana News

Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...